Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (NASDAQ:LXRX) announced upcoming presentations of clinical data for pilavapadin, their investigational AAK1-inhibitor for treating diabetic peripheral neuropathic pain (DPNP), at three major medical meetings.
The presentations will take place at NeuroDiab (September 11-14, Romania), the European Association for the Study of Diabetes (EASD) (September 16-19, Austria), and Arrowhead's 19th Annual Pain Therapeutics Summit (October 13-14, California). Key data from the Phase 2b PROGRESS trial and pilavapadin's potential as a non-opioid treatment option will be discussed by prominent medical experts.
Lexicon Pharmaceuticals (NASDAQ:LXRX) has submitted additional clinical data to the FDA supporting the potential resubmission of Zynquista's New Drug Application (NDA). The submission aims to address concerns raised in a December 2024 complete response letter regarding increased diabetic ketoacidosis risk in type 1 diabetes patients.
The new data comes from three ongoing third-party funded, investigator-initiated studies conducted by Steno Diabetes Center, Joslin Diabetes Center, and the University of Dundee. The company has been granted a Type D meeting with the FDA, with feedback expected by the end of September 2025.
Lexicon Pharmaceuticals (NASDAQ:LXRX) announced it will present new preclinical data for pilavapadin at the NeuPSIG 2025 conference in Berlin. The research demonstrates the drug's effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS).
The findings emphasize the importance of inhibiting pilavapadin's novel target, AAK1, for pain signaling modulation. The company will also present a poster on the study design of PROGRESS, a Phase 2b dose-ranging study of pilavapadin in diabetic peripheral neuropathic pain (DPNP). The presentations suggest potential expansion of pilavapadin's applications beyond its current focus on DPNP.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present data at PAINWeek 2025 regarding the impact of diabetic peripheral neuropathic pain (DPNP) on patients. The presentation, scheduled for September 4, 2025, will showcase insights from a patient survey related to the development of Pilavapadin.
The study focuses on patients' experiences with DPNP despite using current pain relief options. The presentation highlights that diabetic neuropathy affects nearly 50% of diabetes patients during their lifetime, with 25-30% suffering from DPNP specifically, characterized by burning, tingling, and numbness that significantly impacts quality of life.
Lexicon Pharmaceuticals (NASDAQ:LXRX) presented compelling post-hoc analysis results for sotagliflozin at the ESC 2025 Congress in Madrid. The analysis, pooling data from SCORED and SOLOIST-WHF trials with nearly 12,000 participants, demonstrated consistent cardiovascular benefits across all age groups.
The study showed sotagliflozin, a dual SGLT-1 and SGLT-2 inhibitor, reduced heart failure endpoints and major cardiovascular events regardless of age. Key findings include reduction in cardiovascular death and heart failure hospitalization (8.5 vs 11.8 events/100 person-years) and decreased MACE events (5.7 vs 7.1 events/100 person-years). The drug showed particular efficacy in patients over 65, who represented 70% of the study population.
Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced its participation in two upcoming investor conferences in September 2025. The company will present at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 3:00 p.m. ET.
Both presentations will be available via live webcast and replay through Lexicon's investor relations website at investors.lexpharma.com.
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q2 2025 financial results, highlighting significant progress across its pipeline. The company posted net income of $3.3 million ($0.01 per share) compared to a loss of $53.4 million in Q2 2024, with revenues increasing to $28.9 million from $1.6 million year-over-year.
Key developments include ongoing partnership discussions for pilavapadin following Phase 2b results, progress in IND-enabling studies for LX9851 under a $1 billion potential deal with Novo Nordisk, and advancement of the SONATA Phase 3 study for sotagliflozin in HCM. The company ended Q2 with $139 million in cash and investments plus $29 million in restricted cash.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2). This development ensures LXRX's continued listing on the Nasdaq exchange.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET (7:30 a.m. CT) on the same day.
Management will present the financial results and provide a business update during the call. Investors can access the live webcast through the Events page on Lexicon's investor relations website, and those wishing to ask questions can register to receive dial-in information.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present patient-reported data on diabetic peripheral neuropathic pain (DPNP) at the ASPN 2025 conference in Miami Beach, Florida. The presentation focuses on patient experiences with DPNP, a debilitating chronic complication affecting approximately 9 million patients in the U.S.
The research highlights that DPNP impacts 30% of type 1 diabetes patients and 50% of type 2 diabetes patients, causing symptoms like burning pain and numbness in extremities. The study aims to inform the development of pilavapadin, Lexicon's investigational non-opioid treatment for DPNP, and raise awareness among healthcare professionals about patient burden.